Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy-a combined analysis of 713 type 2 diabetic patients

Diabetes, Obesity and Metabolism

Volumn 16, Issue 3, 2014, Pages 248-254

  Seufert, J ^a   Brath, H ^b   Pscherer, S ^c   Borck, A ^d   Bramlage, P ^e   Siegmund, T ^f  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Vienna Tech   (Austria)

^c Klinik Traunstein Medizinische Klinik Diabetologie   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e Institut für Pharmakologie und Präventive Medizin   (Germany)

^f KLINIKUM BOGENHAUSEN   (Germany)

Author keywords

Hypoglycaemia; Insulin; Nocturnal; Symptomatic

Indexed keywords

BASAL PLUS INSULIN; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RETROSPECTIVE STUDY;

HYPOGLYCAEMIA; INSULIN; NOCTURNAL; SYMPTOMATIC;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893797234     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12211     Document Type: Article

References (38)

1. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011; 14: 665-671.
2. Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012; 124: 124-132.
3. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45: 937-948.
4. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176.
5. Bonafede MM, Kalsekar A, Pawaskar M et al. Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocr Disord 2011; 11: 3.
6. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001; 23: 1311-1320.
7. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007; 33: 1014-1029.
8. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084.
9. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S18-24.
10. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
11. American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36(Suppl. 1): S11-66.
12. Levich BR. Diabetes management: optimizing roles for nurses in insulin initiation. J Multidiscip Healthc 2011; 4: 15-24.
13. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and LANTUS Study Group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10: 1178-1185.
14. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab 2011; 13: 1020-1027.
15. Nicolucci A, Del Prato S, Vespasiani G. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. Diabetes Care 2011; 34: 2524-2526.
16. Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 2011; 17: 395-403.
17. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
18. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
19. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263-269.
20. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
21. Payne WW, Poulton EP. An unusual type of insulin reaction in a diabetic patient. Proc R Soc Med 1927; 21: 251.
22. Barnett AH, Cradock S, Fisher M, Hall G, Hughes E, Middleton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010; 64: 1121-1129.
23. McAulay V, Frier BM. Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin Pharmacother 2003; 4: 1141-1156.
24. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-183.
25. Gurlek A, Erbas T, Gedik O. Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy. Exp Clin Endocrinol Diabetes 1999; 107: 220-224.
26. Leese GP, Wang J, Broomhall J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26: 1176-1180.
27. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003; 20: 1016-1021.
28. Donnelly LA, Morris AD, Frier BM et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749-755.
29. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28: 2948-2961.
30. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161: 1653-1659.
31. Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, Hoffman RM. Hypoglycemia in stable, insulin-treated veterans with type 2 diabetes: a prospective study of 1662 episodes. J Diabetes Complications 2005; 19: 10-17.
32. Holstein A, Plaschke A, Egberts EH. Clinical characterisation of severe hypoglycaemia--a prospective population-based study. Exp Clin Endocrinol Diabetes 2003; 111: 364-369.
33. Berntorp K, Haglund M, Larsen S, Petruckevitch A, Landin-Olsson M. Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden. Prim Care Diabetes 2011; 5: 89-94.
34. Sämann A, Lehmann T, Heller T et al. A retrospective study on the incidence and risk factors of severe hypoglycemia in primary care. Fam Pract 2013; 30: 290-293.
35. Miller ME, Bonds DE, Gerstein HC et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340: b5444.
36. Cryer PE. Are gender differences in the responses to hypoglycemia relevant to iatrogenic hypoglycemia in type 1 diabetes? J Clin Endocrinol Metab 2000; 85: 2145-2147.
37. Parekh B. Mechanisms of the blunting of the sympatho-adrenal response: a theory. Curr Diabetes Rev 2009; 5: 79-91.
38. Bastyr EJ 3rd, Huang Y, Brunelle RL, Vignati L, Cox DJ, Kotsanos JG. Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro. Diabetes Obes Metab 2000; 2: 39-46.